UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/15.01.25 | Real-time BOERSE MUENCHEN 16:40:06 18/06/2024 BST | ||
| 5.46 EUR | -4.88% |
|
| Current month | +21.87% | ||
| 1 month | +38.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 5.46 | -4.88% |
| 17/06/24 | 5.74 | -7.42% |
| 14/06/24 | 6.2 | +3.33% |
| 13/06/24 | 6 | +3.81% |
| 12/06/24 | 5.78 | -8.69% |
Real-time BOERSE MUENCHEN
Last update June 18, 2024 at 04:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC49Q1 |
| ISIN | DE000HC49Q12 |
| Date issued | 20/02/2023 |
| Strike | 450 $ |
| Maturity | 15/01/2025 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 1.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.55 € |
|---|---|
| Lowest since issue | 1.36 € |
| Spread | 0.03 € |
| Spread % | 0.55% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Warrants
- Warrant
